<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238407</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 76/02</org_study_id>
    <secondary_id>EU-20529</secondary_id>
    <nct_id>NCT00238407</nct_id>
  </id_info>
  <brief_title>Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>Docetaxel and Cisplatin Chemotherapy Followed by Radiochemotherapy in Patients With Inoperable, Locally Advanced Esophageal Cancer, A Multicenter Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Docetaxel and&#xD;
      cisplatin may also make tumor cells more sensitive to radiation therapy. Giving docetaxel and&#xD;
      cisplatin together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving docetaxel and cisplatin together&#xD;
      with radiation therapy works in treating patients with locally advanced esophageal cancer&#xD;
      that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the local tumor-control rate in patients with locally advanced, unresectable&#xD;
           esophageal cancer treated with docetaxel, cisplatin, and radiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the feasibility of this regimen in these patients.&#xD;
&#xD;
        -  Determine the adverse reactions of this regimen in these patients.&#xD;
&#xD;
        -  Determine local- and distant-failure and time to local- and distant-failure in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the long-term survival rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine whether early improvement of dysphagia is a predictive marker in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine quality of life and clinical benefit in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22,&#xD;
      43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo&#xD;
      radiotherapy once daily, 5 days a week, for 7 weeks.&#xD;
&#xD;
      Quality of life is assessed at baseline, at day 22 and 43 during treatment, and then every 3&#xD;
      months for 1 year after completion of study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients without local failure measured 6 months after completion of study treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions measured after completion of study treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful completion of therapy measured after completion of study treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysphagia as measured 6 months after completion of study treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel and Cisplatin</intervention_name>
    <description>Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed esophageal cancer, including the gastroesophageal junction&#xD;
&#xD;
               -  Squamous cell or adenocarcinoma&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
          -  Meets 1 of the following staging criteria by endoscopic ultrasound:&#xD;
&#xD;
               -  Cervical (supraclavicular) lesion, meeting 1 of the following stages:&#xD;
&#xD;
                    -  TX, N+ disease&#xD;
&#xD;
                    -  T3-4, NX disease&#xD;
&#xD;
                    -  TX, NX, M1a* disease&#xD;
&#xD;
               -  Thoracic (celiac) lesion, meeting 1 of the following stages:&#xD;
&#xD;
                    -  Unresectable T4, NX disease&#xD;
&#xD;
                    -  TX, NX, M1a* disease&#xD;
&#xD;
               -  Locally advanced resectable tumors, inoperable due to medical reasons NOTE: *M1a&#xD;
                  requires unequivocal abnormality on staging CT scan/endosonography&#xD;
&#xD;
          -  No T1-2, N0 disease&#xD;
&#xD;
          -  All tumors encompassable in 1 radiation field&#xD;
&#xD;
          -  No tumor with esophagotracheal fistula&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No significant arrhythmias&#xD;
&#xD;
          -  No other severe cardiovascular disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No uncontrolled active infection&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No definite contraindication to corticosteroids&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No significant neurologic or psychiatric disorder, including psychotic disorders,&#xD;
             dementia, or seizures, that would preclude giving informed consent&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No other prior or concurrent malignancy except nonmelanoma skin cancer or adequately&#xD;
             treated carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the chest&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior experimental treatment in another clinical trial&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Razvan Popescu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hirslanden Klinik Aarau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Ruhstaller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie. 2010;33(5):222-8. doi: 10.1159/000305094. Epub 2010 Apr 9.</citation>
    <PMID>20502056</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>June 4, 2012</last_update_submitted>
  <last_update_submitted_qc>June 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

